Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)

0.48
Delayed Data
As of Nov 17
 0.00 / 0.00%
Today’s Change
0.45
Today|||52-Week Range
2.32
-60.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$37.6M

Company Description

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. The company's two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.

Contact Information

ContraVir Pharmaceuticals, Inc.
399 Thornall Street
Edison New Jersey 08837
P:(732) 902-4000
Investor Relations:
(732) 902-4028

Employees

Shareholders

Individual stakeholders6.89%
Mutual fund holders3.59%
Other institutional3.21%

Top Executives

James E. SapirsteinChief Executive Officer & Director
John T. CavanChief Financial Officer
John Z. Sullivan-BólyaiChief Medical Officer
Robert T. FosterChief Scientific Officer
Theresa MatkovitsSenior Vice President